Biotechnological Oncopeptides has signed an agreement with Alloga logistics to distribute its multiple myeloma drug, Pepaxti, in Spain. This is a long-term alliance, as the company explains to elEconomista.es. However, its economic value has not transcended.
Alloga has the first logistics warehouse in Spain certified with the Breeam sustainability seal, located in Illescas (Toledo). Yesand will be in charge of delivering this drug to all hospitals in the country. This is a treatment indicated for adults who have received at least three lines of treatment previously. Additionally, it is administered to the patient once a month for half an hour.
The European Medicines Agency (EMA) gave the green light to the therapy in August 2022. Thus, it entered a market worth 130 million. In this way, in 2026 it estimates to obtain sales of 35 million euros.
A year and four months later, the Ministry of Health decided to open its doors. In fact, it gave it a price of 3,529.02 euros per vial, according to the February minutes of the Interministerial Commission on Prices of Medicines and Health Products (CIPM).
Oncopeptides is present in Germany, Spain and Italy. In the latter you are negotiating the price of your medication. Furthermore, in France and the United Kingdom it is in the third phase of its sales plan. It has also just signed an agreement with SCBIO to sell this drug in South Korea. It should be remembered that in 2021 the Swede tried to enter the United States with this medication. However, so far it has not gotten the green light.
On the other hand, the Swedish pharmaceutical company It has a portfolio of drugs in development. These are based on two platforms: one of peptide drug candidates to develop compounds that rapidly and selectively release cytotoxic agents in cancer cells; and the SPiKE platform, which uses “natural killer cells” against viruses and other foreign cells.
The laboratory explained that it is currently focused on researching therapies for multiple myeloma and leukemia, but in the future it will expand its catalog of diseases. Today, they are in the preclinical phase.
Multiple myeloma is a cancer found in a type of white blood cells known as plasma cells, which help fight infections through antibodies. In Spain, 2,693 new cases were detected in 2022 (latest data available).
#Alloga #distribute #Oncopeptides #antitumor #drug #Spain
